The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Patients are already receiving an intravitreal injection as a standard of care, but they are
consenting to receiving a loteprednol drop following the intravitreal injection. This
clinical trial is studying the role of loteprednol (corticosteroid) in reducing pain
following intravitreal injections for patients with age-related macular degeneration. As of
now, there is no definitive pain management technique following intravitreal injections.
Loteprednol is a corticosteroid widely used in ophthalmology to treat pain and inflammation,
however, it has not been studied as a treatment for pain following intravitreal injections.
Our overall goal is to manage pain to improve quality of care after intravitreal injections.
Participants will be given either loteprednol, nepafenac (NSAID comparison), or artificial
tears following one visit for an intravitreal injection to test how effective loteprednol is
in pain reduction. Pain levels will be assessed by asking participants over the phone about
their pain from a scale of 0 to 10 at three different times over a 1-week period. Artificial
tear and medication usage will also be tracked over a 1-week period.
Phase:
N/A
Details
Lead Sponsor:
Virginia Polytechnic Institute and State University